The FeNO by NIOX® podcast

Did you know the world’s first FeNO testing machine was developed by the team behind NIOX®? It was 1.5m tall and 70cm wide! Our cutting-edge technology has come a long way since then. So this time, here’s a little about the story of the FeNO evolution. 

Fractional exhaled nitric oxide, known as FeNO, testing and spirometry can make a valuable pairing in asthma care. In this episode, we’re looking at how these two pieces of the respiratory puzzle can help to complete the picture.

Testing a patient’s level of fractional exhaled nitric oxide, known as FeNO, is a valuable tool in asthma diagnosis and management so it’s important to know you can rely on the results.1 In this episode, we’re explaining how FeNO testing with NIOX® makes it possible.

We spoke to FeNO expert Professor Kjell Alving about the science behind foods that affect a patient’s level of fractional exhaled nitric oxide, or FeNO. There’s more to it than meets the eye so let’s get started.

As athletes strive to achieve their goals, one area of increasing focus is the role of respiratory health in sports performance. Studies show that FeNO testing is one of the tools that can help. FeNO isn’t just for elite performers either. The role of FeNO in the management of daily exercise-induced problems among school children has also been examined. Today, we’re talking about some of the highlights.

Research has shown that cigarette smoking can reduce fractional exhaled nitric oxide – or FeNO – by around 60%1but what about vaping? Electronic or ‘e-cigarettes’ have gained significant popularity in recent years as an alternative to traditional tobacco smoking. However, concerns have been raised regarding the potential impact on public health. One aspect of particular interest to the respiratory community is whether vaping affects FeNO levels. In this episode, we explore the evidence.

Devices that measure FeNO have markedly influenced the clinical decision-making of healthcare professionals and helped alter treatment plans for patients with asthma. However, true accuracy and reproducibility of the results depend on various factors, including the proper use of the FeNO testing device. In this episode, we discuss the value of audio guides as part of this process.

This month marks 25 years of FeNO testing by NIOX®, a company founded by the same scientists who originally discovered its benefits in asthma care.

To mark World Asthma Day, in this episode our lead nurse for education and support, Karen Frankland, talks to broadcaster Will Luscombe to discuss how asthma treatment can be enhanced with the help of FeNO testing.

A FeNO level greater than 40 parts per billion – or ppb – means asthma is seven times more likely, making FeNO a useful biomarker in suspected cases. But why is FeNO higher in asthma patients? This episode looks at the science.

Over-reliance on short-acting β2-agonists, known as SABA, may indicate poor asthma control. Some people are collecting more than 50 canisters a year when the recommendation is one or two! In this episode, we look at the facts and...

In this episode, we’re looking at what is important when measuring FeNO levels and how the technology behind NIOX VERO® addresses these needs.

One part per billion. It’s difficult to picture it but this microscopic measure is an intrinsic element of the technology behind FeNO testing and its practical application in asthma care.

As many people know, FeNO stands for fractional exhaled nitric oxide. Changes in individual FeNO levels provide vital clues to how asthma treatment is working. Interpreting the variations is quite straightforward. This episode looks in detail at using FeNO testing to achieve everyone’s personal best.

Measuring FeNO is straightforward and gives results at the point-of-care. The American Thoracic Society – known as the ATS – sets out clear cut-off points defining low, normal and high FeNO. But where do you begin?

FeNO testing has really gained traction over the last five years and thousands of physicians use it every day to improve patient outcomes. Most national and international societies recognise the value of FeNO testing to help achieve more accurate diagnosis and better asthma management, and now include FeNO in their recommendations.

Symptoms worsen for around a third of pregnant woman with asthma yet many are reluctant to take medication...

What has the chemical formula KMnO4, is purplish-black when solid and intense pink-purple in solution? It’s potassium permanganate – and it’s a vital part of FeNO testing! But it’s no mixer. This episode looks inside the NIOX VERO® and examines why alcohol is off-limits for FeNO.

All exhalations are not the same when it comes to testing fractional exhaled nitric oxide (FeNO). Exhaling for 10 seconds for all adult patients is one of the most important steps. This article looks in detail at why this timing is so central to success.

In this episode, we talk about fractional exhaled nitric oxide (FeNO) and how monitoring their FeNO levels can reduce the impact asthma has on patients’ quality of life.

We’re talking about treatment for asthma in this episode, specifically inhaled corticosteroids and patient adherence, with a look at how FeNO testing can help.

In this episode, we discuss how certain types of food affect FeNO and what information clinicians can give patients to ensure reliable results.

Knowing your patient’s FeNO level can help diagnose asthma and improve outcomes. This episode explains how to interpret FeNO test results into meaningful data for patient care, as well as savings for healthcare budgets.

In this episode of the podcast, we’re looking at a summary of the latest research into pulmonary assessment during the pandemic and how FeNO testing is not an aerosol-generating procedure so it’s safe to continue using.

Asthma exacerbations cause distress and can easily lead to a medical emergency. This episode of the podcast examines the effect that flare-ups can have on patients’ quality of life and how regular FeNO testing can help to reduce the risk.

In this episode of the podcast, we look at whether FeNO testing can be used as an alternative to sputum and blood eosinophils to support asthma diagnosis.

One of the key moments at ERS 2021 came in the form of a friendly and informative debate: FeNO* for the diagnosis of asthma in adults: Friend or foe?1 Dr Iñigo Ojanguren Arranz, from the Respiratory Department of Vall d’Hebron University Hospital in Barcelona, outlined the reasons he considers FeNO a friend. Head of Pneumology and Professor of Respiratory Medicine at the University of Liège, Renaud Louis, gave a rebuttal, asserting his thoughts on why FeNO might be a foe.